Support our Foundation of Myology project
1670 news items
Patient care
The benefits of the ketogenic diet in the treatment of myasthenia gravis
On 10/07/2026
German clinicians have investigated the benefits of the ketogenic diet (very high in fat and low in carbohydrates) in autoimmune myasthenia gravis, following on from…
Research
In myasthenia gravis, complement inhibitors increase life expectancy… and cardiovascular risk!
On 08/07/2026
Two German researchers investigated the benefits and potential complications – particularly cardiovascular ones – of a new class of drugs used to treat refractory forms…
Research
A review of myositis in the NEJM, authored by two French experts
On 24/06/2026
In line with their research over several decades and the advances they have already spearheaded, Professors Olivier Benveniste and Yves Allenbach (the Inflammatory Myopathies &…
Research
Results of the cemdisiran trial in myasthenia gravis have been published
On 22/06/2026
In 13 countries, including France, the Phase III Nimble trial evaluated cemdisiran, a small interfering RNA (siRNA) targeting complement component 5, administered subcutaneously, in patients…
Research
Increasing utrophin expression in DMD using CRISPR-Cas9
On 19/06/2026
One therapeutic approach for Duchenne muscular dystrophy (DMD) involves increasing the expression of utrophin to compensate for the absence of dystrophin, with which it shares…
Patient care
Recommendations for the management of neuropsychiatric disorders associated with DMD
On 16/06/2026
The management of neurodevelopmental and psychiatric disorders represents a major unmet need among patients with Duchenne muscular dystrophy (DMD). As part of the European BIND…
Research
An analysis of BNDMR data on myasthenia gravis
On 16/06/2026
A study of 3,963 patients with myasthenia gravis included in the National Rare Diseases Database (BNDMR) provides valuable insights into patient care at rare disease…
Patient care
Pioglitazone evaluated in inclusion body myositis during a phase I trial
On 15/06/2026
Pioglitazone, a selective agonist of the nuclear PPAR-γ receptors, was evaluated in a phase I trial involving 13 patients with inclusion body myositis, all of…
Events
M&Ms – Muscle Monday Seminar –15 June – Dr Cynthia Gagnon (Canada)
On 12/06/2026
Optimizing preparation for clinical trials in rare diseases through translational and interdisciplinary research: the NMD experience Monday 15 Juin 2026 from noon to 1pm (Paris…
Events
ERN EURO-NMD webinar, 18 June: Prof. Grazia Devigili (Italy)
On 12/06/2026
Episode 8 – Skin Biopsy in Small Fiber Neuropathy (in EURO-NMD Neuropathology Webinar Series) Thursday 18 June 2026 – 16:00-17:00 Paris time Speaker: Prof. Grazia Devigili…
Patient care
Very late-onset myasthenia gravis: a condition with a good prognosis that requires active treatment
On 11/06/2026
Very late-onset autoimmune myasthenia (VLOM) is becoming increasingly common: appears from the age of 65 onwards, is characterised by a male predominance and a rare…
Events
GenoTher Summit 2026, 17-18 June 2026, Paris
On 08/06/2026
On 17 and 18 June, the GenoTher biocluster is organising the GenoTher Summit 2026 – Accelerating the Future of Genetic Medicine in Paris. Bringing together…
Patient care
Risdiplam (Evrysdi) tablets: a new formulation now available in France
On 08/06/2026
The registration of risdiplam (Evrysdi) film-coated tablets in the French Official Journal has just been published. This new formulation will be available in pharmacies from…
Events
ERN EURO-NMD webinar, 11 June: Prof. Andoni Echaniz Laguna (France)
On 05/06/2026
Episode 7 – Amyloid Neuropathies and Therapeutic Approaches (in EURO-NMD Neuropathology Webinar Series) Thursday 11 June 2026 – 16:00-17:00 Paris time Speaker: Prof. Andoni Echaniz Laguna…
Research
Pyridostigmine and amifampridine evaluated versus placebo in myasthenia gravis
On 04/06/2026
Almost a century after Dr Mary Walker first used pyridostigmine to treat autoimmune myasthenia gravis: the randomised, randomised, double-blind IMPACT-MG trial in the Netherlands compared…
Documentation
Advances in myasthenia gravis – 2026
On 03/06/2026
This document presents a selection of myasthenia gravis research news stories from the past year (ongoing observational studies and clinical trials, scientific and medical publications…).…
Research
Encouraging results for efgartigimod in juvenile myasthenia gravis
On 03/06/2026
Approved in France since 2022, efgartigimod (Vyvgart®) is currently indicated for adults with generalised autoimmune myasthenia gravis with anti-RACh antibodies. A multicentre retrospective study conducted…
Research
Researchers from the CRM’s REDs team attended the IDMC-15 conference
On 02/06/2026
The 15th International Myotonic Dystrophy Consortium Congress (IDMC-15), which brings together international scientists specialising in myotonic dystrophy every two years, was held this year from…
Events
4th European Myasthenia Gravis Day on 2 June
On 02/06/2026
2 June 2026 marks the 4th European Myasthenia Gravis Day. Created on the initiative of the All United for MG coalition, which brings together patient…
Research
For a comprehensive overview of diseases associated with the GBE1 gene
On 01/06/2026
American clinicians, in collaboration with the patient organisation APBD Research Foundation, have investigated muscle-affecting disorders linked to the GBE1 gene, which encodes the glycogen branching…